DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+1.54%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$266M
AUM Growth
+$266M
(+15%)
Cap. Flow
+$27.1M
Cap. Flow
% of AUM
10.17%
Top 10 Holdings %
Top 10 Hldgs %
46.64%
Holding
94
New
15
Increased
27
Reduced
15
Closed
6
Top Buys
| 1 |
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
|
$3.74M |
| 2 |
Quince Therapeutics
QNCX
|
$2.78M |
| 3 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$2.25M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
$2.18M |
| 5 |
Accuray
ARAY
|
$2.03M |
Top Sells
| 1 |
GNCA
Genocea Biosciences, Inc.
GNCA
|
$4.92M |
| 2 |
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
|
$1.59M |
| 3 |
ADXS
Advaxis, Inc.
ADXS
|
$1.2M |
| 4 |
Arbutus Biopharma
ABUS
|
$884K |
| 5 |
Savara
SVRA
|
$813K |
Sector Composition
| 1 | Healthcare | 91.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GNCA
26
DELISTED
Genocea Biosciences, Inc.
GNCA
| $2.88M | 1.08% |
734,422
-1,255,231
| -63% | -$4.92M |
|
|
27
Quince Therapeutics
QNCX
$85.9M
| $2.78M | 1.05% |
+65,400
| New | +$2.78M |
|
|
PHAS
28
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $2.62M | 0.99% |
200,013
+127,513
| +176% | +$1.67M |
|
|
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
| $2.51M | 0.94% |
349,996
+71,185
| +26% | +$510K |
|
30
ProQR Therapeutics
PRQR
$237M
| $2.38M | 0.89% |
261,521
| – | – |
|
|
TBIO
31
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $2.25M | 0.85% |
+178,306
| New | +$2.25M |
|
|
CSII
32
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.2M | 0.83% |
51,200
-5,000
| -9% | -$215K |
|
|
BEAT
33
DELISTED
BioTelemetry, Inc.
BEAT
| $2.18M | 0.82% |
45,300
+10,500
| +30% | +$506K |
|
|
EPZM
34
DELISTED
Epizyme, Inc
EPZM
| $2.18M | 0.82% |
+173,536
| New | +$2.18M |
|
35
Corbus Pharmaceuticals
CRBP
$115M
| $2.06M | 0.77% |
297,300
-7,700
| -3% | -$53.4K |
|
|
36
Accuray
ARAY
$157M
| $2.03M | 0.76% |
+524,300
| New | +$2.03M |
|
|
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $1.92M | 0.72% |
808,000
| – | – |
|
|
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.86M | 0.7% |
118,314
-5,000
| -4% | -$78.7K |
|
39
Ardelyx
ARDX
$1.53B
| $1.83M | 0.69% |
681,759
+5,000
| +0.7% | +$13.5K |
|
|
KDMN
40
DELISTED
Kadmon Holdings, Inc.
KDMN
| $1.83M | 0.69% |
886,177
+129,000
| +17% | +$266K |
|
41
Indaptus Therapeutics
INDP
$7.19M
| $1.81M | 0.68% |
415,989
+34,200
| +9% | +$148K |
|
42
Viking Therapeutics
VKTX
$3.04B
| $1.74M | 0.65% |
209,200
+30,000
| +17% | +$249K |
|
|
NVRO
43
DELISTED
NEVRO CORP.
NVRO
| $1.7M | 0.64% |
26,210
-5,000
| -16% | -$324K |
|
44
SCYNEXIS
SCYX
$34.9M
| $1.67M | 0.63% |
1,272,927
| – | – |
|
|
ACHN
45
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $1.62M | 0.61% |
604,884
-16,298
| -3% | -$43.7K |
|
|
AUTL
46
Autolus Therapeutics
AUTL
$399M
| $1.61M | 0.61% |
+100,000
| New | +$1.61M |
|
47
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.56M | 0.59% |
410,888
-87,527
| -18% | -$332K |
|
48
Inogen
INGN
$216M
| $1.54M | 0.58% |
23,000
+13,100
| +132% | +$874K |
|
49
NextCure
NXTC
$13.5M
| $1.44M | 0.54% |
+96,100
| New | +$1.44M |
|
|
GMDA
50
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $1.4M | 0.53% |
+275,000
| New | +$1.4M |
|